| Drug Type Therapeutic vaccine, Dendritic cell vaccine | 
| Synonyms Autologous monocyte-derived DCs pulsed withEBV-associated antigen(Zhongshan Hengsai) | 
| Target | 
| Action inhibitors | 
| Mechanism EBV Protein inhibitors | 
| Therapeutic Areas | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Epstein-Barr virus associated Nasopharyngeal Carcinoma | Phase 1 | China  | 04 Dec 2023 | |
| Nasopharyngeal Carcinoma | Phase 1 | China  | 04 Dec 2023 | |
| Epstein-Barr Virus-Related Lymphoma | Phase 1 | China  | 10 Jun 2023 | |
| Hematologic Neoplasms | Phase 1 | China  | - | 16 Jan 2023 | 
| Phase 1 | 9 | lneeyoggpj(kcwiexaxaw) = qdfvpsdnbt dgzqceyumo (seupxfmuxg ) | - | 11 Dec 2023 | 





